Valganciclovir Safe and Well-Tolerated in Patients With Idiopathic Pulmonary Fibrosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of the American Thoracic Society
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase I Randomized, Controlled Trial of Valganciclovir in Idiopathic Pulmonary Fibrosis
Ann Am Thorac Soc 2021 Mar 19;[EPub Ahead of Print], TS Blackwell, JC Hewlett, WR Mason, S Martin, J Del Greco, G Ding, P Wu, LH Lancaster, JE Loyd, RB Dudenhofer, ML Salisbury, JA KropskiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.